Related Experiment Video

Updated: Jul 18, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K

Sacubitril/Valsartan Shows Improvement of the Cardio-Ankle Vascular Index in a Hypertensive Patient

Kazuhiro Shimizu1, Tsuyoshi Tabata2, Masahiro Iwakawa1

  • 1Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.

International Medical Case Reports Journal
|August 28, 2023
PubMed

Insights

This study shows that angiotensin receptor-neprilysin inhibitor (ARNI) effectively reduced arterial stiffness in a hypertensive patient. This suggests ARNI may help prevent heart failure by improving cardio-vascular interactions.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Hypertension is a major risk factor for cardiovascular disease.
  • Arterial stiffness, measured by cardio-ankle vascular index (CAVI), is an indicator of vascular health.
  • Traditional antihypertensive medications may not fully address arterial stiffness.

Observation:

  • A 72-year-old male patient presented with hypertension and markedly increased arterial stiffness (CAVI 13.5).
  • Initial treatment with valsartan (80 mg/day) for three months showed a minimal decrease in CAVI (to 13.0) and persistent blood pressure fluctuations.
  • Switching to angiotensin receptor-neprilysin inhibitor (ARNI) at increasing doses (up to 400 mg) led to improved CAVI, independent of immediate blood pressure readings.

Findings:

  • Angiotensin receptor-neprilysin inhibitor (ARNI) demonstrated a dose-dependent improvement in arterial stiffness (CAVI).
  • The reduction in CAVI suggests a beneficial effect of ARNI on vascular properties beyond its blood pressure-lowering effect.
  • This case highlights the potential of ARNI in managing arterial stiffness in hypertensive patients.

Implications:

  • Targeting cardio-vascular interactions with medications like ARNI may offer a novel strategy for preventing heart failure.
  • Further research into ARNI's impact on arterial stiffness and long-term cardiovascular outcomes is warranted.
  • Personalized hypertension management considering vascular parameters like CAVI could improve patient prognosis.

Keywords:
angiotensin receptor-neprilysin inhibitorarterial stiffnesscardio ankle vascular indexhypertension

More Related Videos

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

3.2K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.3K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
778
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
679
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
689
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
566